sPECAM-1 and sVCAM-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy
Aim: To analyze the relationship between pretreatment clinical or histological features and the levels of soluble platelet-endothelial cell adhesion molecule-1 (sPECAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1), to determine their serum concentration in responders and nonresponders,...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2009-03-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/1756283X08100666 |
| _version_ | 1828900613283381248 |
|---|---|
| author | Michal Kukla Krystyna Zwirska-Korczala Andrzej Gabriel Ewa Janczewska-Kazek Agnieszka Berdowska Andrzej Wiczkowski Barbara Rybus-Kalinowska Mariusz Kalinowski Adam Ziolkowski Elzbieta Wozniak-Grygiel Marek Waluga Blazej Nowak |
| author_facet | Michal Kukla Krystyna Zwirska-Korczala Andrzej Gabriel Ewa Janczewska-Kazek Agnieszka Berdowska Andrzej Wiczkowski Barbara Rybus-Kalinowska Mariusz Kalinowski Adam Ziolkowski Elzbieta Wozniak-Grygiel Marek Waluga Blazej Nowak |
| author_sort | Michal Kukla |
| collection | DOAJ |
| description | Aim: To analyze the relationship between pretreatment clinical or histological features and the levels of soluble platelet-endothelial cell adhesion molecule-1 (sPECAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1), to determine their serum concentration in responders and nonresponders, to evaluate the behavior under antiviral therapy, to explain their relationship in response to therapy and to assess the association between these two molecules in chronic hepatitis C (CHC). Methods: The study analyzed 65 CHC patients, including 50 patients (Group 1) with marked fibrosis treated with peginterferon plus ribavirin, 15 patients without fibrosis (Group 2) and 13 healthy volunteers (the control group, Group 3). sPECAM-1 and sVCAM-1 levels were assessed by an immunoenzymatic method (ELISA) before and after therapy. Results: sVCAM-1 and sPECAM-1 serum concentrations increased significantly in CHC patients (p<0.001). sPECAM-1 levels corresponded to inflammatory grade (p = 0.03) and fibrosis stage (p = 0.01). sVCAM-1 increased only in advanced fibrosis. After therapy, sPECAM-1 levels decreased significantly (p<0.001) with no difference between responders and nonresponders. sPECAM-1 correlated positively with inflammatory activity (p = 0.02), fibrosis stage (p<0.001), sVCAM-1 (r = 0.56, p<0.001) and alanine aminotransferase activity (r = 0.30, p = 0.05). Receiver operating characteristic curve analysis showed a good discriminant power of serum sPECAM-1 concentrations for detection of liver fibrosis — stage 0 versus stage 1—3, AUC 0.81; cut-off 221.0 ng/ml and a fair discriminant power for distinguishing bridging fibrosis, AUC 0.78; cut-off 237.1 ng/ml. Conclusions: Hepatitis C virus (HCV) infection results in upregulation of sPECAM-1 and sVCAM-1. sPECAM-1 levels are related to necroinflammatory activity and may also identify patients with advanced fibrosis. The sPECAM-1 value was decreased by therapy but its measurement cannot predict therapy outcome and confirm HCV persistence. sPECAM-1 may influence VCAM-1 expression. |
| first_indexed | 2024-12-13T15:50:04Z |
| format | Article |
| id | doaj.art-31f5d1af3c004db6b074474c625764c5 |
| institution | Directory Open Access Journal |
| issn | 1756-283X |
| language | English |
| last_indexed | 2024-12-13T15:50:04Z |
| publishDate | 2009-03-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Gastroenterology |
| spelling | doaj.art-31f5d1af3c004db6b074474c625764c52022-12-21T23:39:32ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-283X2009-03-01210.1177/1756283X08100666sPECAM-1 and sVCAM-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapyMichal KuklaKrystyna Zwirska-KorczalaAndrzej GabrielEwa Janczewska-KazekAgnieszka BerdowskaAndrzej WiczkowskiBarbara Rybus-KalinowskaMariusz KalinowskiAdam ZiolkowskiElzbieta Wozniak-GrygielMarek WalugaBlazej NowakAim: To analyze the relationship between pretreatment clinical or histological features and the levels of soluble platelet-endothelial cell adhesion molecule-1 (sPECAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1), to determine their serum concentration in responders and nonresponders, to evaluate the behavior under antiviral therapy, to explain their relationship in response to therapy and to assess the association between these two molecules in chronic hepatitis C (CHC). Methods: The study analyzed 65 CHC patients, including 50 patients (Group 1) with marked fibrosis treated with peginterferon plus ribavirin, 15 patients without fibrosis (Group 2) and 13 healthy volunteers (the control group, Group 3). sPECAM-1 and sVCAM-1 levels were assessed by an immunoenzymatic method (ELISA) before and after therapy. Results: sVCAM-1 and sPECAM-1 serum concentrations increased significantly in CHC patients (p<0.001). sPECAM-1 levels corresponded to inflammatory grade (p = 0.03) and fibrosis stage (p = 0.01). sVCAM-1 increased only in advanced fibrosis. After therapy, sPECAM-1 levels decreased significantly (p<0.001) with no difference between responders and nonresponders. sPECAM-1 correlated positively with inflammatory activity (p = 0.02), fibrosis stage (p<0.001), sVCAM-1 (r = 0.56, p<0.001) and alanine aminotransferase activity (r = 0.30, p = 0.05). Receiver operating characteristic curve analysis showed a good discriminant power of serum sPECAM-1 concentrations for detection of liver fibrosis — stage 0 versus stage 1—3, AUC 0.81; cut-off 221.0 ng/ml and a fair discriminant power for distinguishing bridging fibrosis, AUC 0.78; cut-off 237.1 ng/ml. Conclusions: Hepatitis C virus (HCV) infection results in upregulation of sPECAM-1 and sVCAM-1. sPECAM-1 levels are related to necroinflammatory activity and may also identify patients with advanced fibrosis. The sPECAM-1 value was decreased by therapy but its measurement cannot predict therapy outcome and confirm HCV persistence. sPECAM-1 may influence VCAM-1 expression.https://doi.org/10.1177/1756283X08100666 |
| spellingShingle | Michal Kukla Krystyna Zwirska-Korczala Andrzej Gabriel Ewa Janczewska-Kazek Agnieszka Berdowska Andrzej Wiczkowski Barbara Rybus-Kalinowska Mariusz Kalinowski Adam Ziolkowski Elzbieta Wozniak-Grygiel Marek Waluga Blazej Nowak sPECAM-1 and sVCAM-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy Therapeutic Advances in Gastroenterology |
| title | sPECAM-1 and sVCAM-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy |
| title_full | sPECAM-1 and sVCAM-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy |
| title_fullStr | sPECAM-1 and sVCAM-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy |
| title_full_unstemmed | sPECAM-1 and sVCAM-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy |
| title_short | sPECAM-1 and sVCAM-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy |
| title_sort | specam 1 and svcam 1 role in pathogenesis and diagnosis of chronic hepatitis c and association with response to antiviral therapy |
| url | https://doi.org/10.1177/1756283X08100666 |
| work_keys_str_mv | AT michalkukla specam1andsvcam1roleinpathogenesisanddiagnosisofchronichepatitiscandassociationwithresponsetoantiviraltherapy AT krystynazwirskakorczala specam1andsvcam1roleinpathogenesisanddiagnosisofchronichepatitiscandassociationwithresponsetoantiviraltherapy AT andrzejgabriel specam1andsvcam1roleinpathogenesisanddiagnosisofchronichepatitiscandassociationwithresponsetoantiviraltherapy AT ewajanczewskakazek specam1andsvcam1roleinpathogenesisanddiagnosisofchronichepatitiscandassociationwithresponsetoantiviraltherapy AT agnieszkaberdowska specam1andsvcam1roleinpathogenesisanddiagnosisofchronichepatitiscandassociationwithresponsetoantiviraltherapy AT andrzejwiczkowski specam1andsvcam1roleinpathogenesisanddiagnosisofchronichepatitiscandassociationwithresponsetoantiviraltherapy AT barbararybuskalinowska specam1andsvcam1roleinpathogenesisanddiagnosisofchronichepatitiscandassociationwithresponsetoantiviraltherapy AT mariuszkalinowski specam1andsvcam1roleinpathogenesisanddiagnosisofchronichepatitiscandassociationwithresponsetoantiviraltherapy AT adamziolkowski specam1andsvcam1roleinpathogenesisanddiagnosisofchronichepatitiscandassociationwithresponsetoantiviraltherapy AT elzbietawozniakgrygiel specam1andsvcam1roleinpathogenesisanddiagnosisofchronichepatitiscandassociationwithresponsetoantiviraltherapy AT marekwaluga specam1andsvcam1roleinpathogenesisanddiagnosisofchronichepatitiscandassociationwithresponsetoantiviraltherapy AT blazejnowak specam1andsvcam1roleinpathogenesisanddiagnosisofchronichepatitiscandassociationwithresponsetoantiviraltherapy |